Table 1.
Baseline characteristics of 100 patients.
| Total (n = 100) | Good collaterals (n = 26) | Poor collaterals (n = 74) | p Value | |
|---|---|---|---|---|
| Demographics | ||||
| Sex (female), n (%) | 20 (20.0) | 8 (30.8) | 12 (16.2) | 0.153 |
| Age, y; mean (SD) | 63.0 ± 10.7 | 63.4 ± 11.6 | 62.9 ± 10.5 | 0.834 |
| Hypertension, n (%) | 65 (65.0) | 16 (61.5) | 49 (66.2) | 0.811 |
| Diabetes mellitus, n (%) | 28 (28.0) | 3 (11.5) | 25 (33.8) | 0.041 |
| Atrial fibrillation, n (%) | 32 (32.0) | 7 (26.9) | 25 (33.8) | 0.628 |
| Stroke, n (%) | 27 (27.0) | 6 (23.1) | 21 (28.4) | 0.798 |
| Smoking, n (%) | 58 (58.0) | 13 (50.0) | 45 (60.8) | 0.364 |
| Clinical and imaging features | ||||
| NIHSS, mean (SD) | 15.7 ± 4.5 | 14.5 ± 2.8 | 16.1 ± 4.9 | 0.104 |
| ASPECT, mean (SD) | 9.0 (7.0–10.0) | 9.0 (7.8–10.0) | 9.0 (7.0–10.0) | 0.805 |
| SBP after EVT, mean (SD) | 139.7 ± 23.5 | 140.3 ± 21.2 | 139.5 ± 24.4 | 0.891 |
| DBP after EVT, mean (SD) | 82.6 ± 14.7 | 84.7 ± 18.7 | 81.8 ± 13.1 | 0.383 |
| sCCT, median (IQR) | 2.170 (1.830–3.000) | 2.000 (1.830–2.668) | 2.193 (1.830–3.000) | 0.521 |
| hCCT, median (IQR) | 2.250 (1.670–2.830) | 2.330 (2.000–3.270) | 2.170 (1.670–2.670) | 0.161 |
| cCCT, median (IQR) | 0.000 (−0.153–0.333) | −0.068 (−0.341–0.228) | 0.046 (−0.132–0.376) | 0.048 |
| Number of passes, median (IQR) | 1 (1 2) | 1 (1 2) | 2 (1 2) | 0.088 |
| NRV stenosis, n (%) | 52 (52.0) | 10 (38.5) | 42 (56.8) | 0.118 |
| OPT, min, median (IQR) | 337.5 (232.3–535.8) | 483.5 (315.5–633.3) | 314.5 (229.8–468.3) | 0.024 |
| OCT, min, median (IQR) | 324.5 (243.5–549.5) | 508.0 (322.3–473.5) | 322.5 (235.8–473.5) | 0.022 |
| DPT, min, median (IQR) | 50.0 (34.8–88.5) | 72.0 (47.8–108.0) | 46.5 (31.8–79.3) | 0.014 |
| ORT, min, median (IQR) | 410.0 (319.8–615.8) | 548.5 (360.8–788.8) | 386.5 (309.8–575.3) | 0.024 |
| TOAST 0.212 | ||||
| LAA, n (%) | 60 (60.0) | 18 (69.2) | 42 (56.8) | |
| Cardioemblism, n (%) | 26 (26.0) | 7 (26.9) | 19 (25.7) | |
| Undetermined, n (%) | 14 (14.0) | 1 (3.8) | 13 (17.6) | |
| Intravenous thrombolysis | 0.720 | |||
| NO | 76 (76.0) | 21 (80.8) | 55 (74.3) | |
| rt‐PA | 17 (17.0) | 4 (15.4) | 13 (17.6) | |
| UK | 7 (7.0) | 1 (3.8) | 6 (8.1) | |
| Final mTICI | 0.402 | |||
| Final mTICI 2B, n (%) | 43 (43.0) | 13 (50.0) | 30 (40.5) | |
| Final mTICI 3, n (%) | 57 (57.0) | 13 (50.0) | 44 (59.5) | |
| ICH, n (%) | 41 (41.0) | 8 (30.8) | 33 (44.6) | 0.218 |
| Infarct volume, cm3, median (IQR) | 49.9 (17.3–128.8) | 32.7 (4.6–105.9) | 56.8 (21.1–132.1) | 0.063 |
| 90‐d mRS ≤ 2 | 43 (43.0) | 16 (61.5) | 27 (36.5) | 0.038 |
ASPECTS, Alberta Stroke Program Early CT Score; cCCT, change of CCT; DBP, diastolic blood pressure; DPT, door‐to‐puncture time; hCCT, CCT of healthy side; ICH, intracerebral hemorrhage; mTICI, modified thrombolysis in cerebral ischemia; NIHSS, National Institutes of Health Stroke Scale; NRV stenosis, non‐responsible vessel stenosis; OCT, onset‐to‐collateral assessment time; OPT, onset‐to‐puncture time; ORT, onset‐to‐reperfusion time; rt‐PA, Recombinant Tissue Plasminogen Activator; SBP, systolic blood pressure; sCCT, CCT of stoke side; UK, Urokinase.